News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Major explosion at Valero's Port Arthur refinery caused a large fire and shelter-in-place orders, risking U.S. fuel-supply disruption.
  • Dollar weakened after President Trump paused a planned strike on Iran's power grid and called talks 'productive,' easing immediate escalation fears.
  • Iran rejected the U.S. claim of 'productive' talks, maintaining geopolitical uncertainty and complicating de-escalation prospects.
  • Oil prices swung in a volatile session as markets weighed the refinery blast and shifting Middle East tensions.
  • Analysts pitched a long in Astronics at $66 with an $85 target, citing rising aircraft-lighting demand and a revenue-adding acquisition.
  • Analysts recommended buying Preformed Line Products at $275 with a $330 target, citing exposure to grid and broadband upgrades and low leverage.

Latest Articles

KeyBanc Keeps Sector Weight on Avista After 2025 RFP Selections; Capital Plan, Rate Filing Highlight Path Forward

KeyBanc Keeps Sector Weight on Avista After 2025 RFP Selections; Capital Plan, Rate Filing Highlight Path Forward

KeyBanc has reaffirmed a Sector Weight rating on Avista (AVA) after the utility announced the winners of its 2025 Request for Proposals. The selected portfolio, which combines company-owned resources and power purchase agreements, is expected to drive $250 million to $350 million of incremental capital and may support an uplift to Avista's long-ter…

FDA Lifts Hold on Intellia’s Nerve-Disease Gene Therapy Trial, Enabling Restart of Patient Enrollment

FDA Lifts Hold on Intellia’s Nerve-Disease Gene Therapy Trial, Enabling Restart of Patient Enrollment

The U.S. regulator has lifted a clinical hold on Intellia Therapeutics’ late-stage trial of its CRISPR-based therapy, nexiguran ziclumeran, in patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN). Intellia said it will resume patient enrollment as soon as possible after agreeing to enhanced safety monitoring measures. A…

HSBC Advises Investors to Maintain Aggressive Risk-On Posture

HSBC Advises Investors to Maintain Aggressive Risk-On Posture

HSBC is urging clients to stay positioned for further gains in risk assets, remaining overweight equities, high-yield credit, emerging-market debt and gold, while underweighting developed-market sovereigns, investment-grade credit and oil. The bank says geopolitics is secondary to U.S. rates, rates volatility and near-term growth expectations, and …

TSX Futures Inch Up as Commodities Gain; Markets Await Fed, BoC Decisions

TSX Futures Inch Up as Commodities Gain; Markets Await Fed, BoC Decisions

Futures tied to Canada’s primary stock index moved modestly higher as gains in gold and silver helped offset other headwinds. Investors are positioning ahead of Federal Reserve and Bank of Canada policy meetings, with U.S. futures trading mixed and commodities - notably gold and crude - showing notable strength amid trade tensions and severe winter…

CoStar Shares Rally After Third Point Reveals Plans for Activist Push

CoStar Shares Rally After Third Point Reveals Plans for Activist Push

CoStar Group shares jumped after billionaire investor Daniel Loeb’s hedge fund, Third Point, signaled plans for an activist campaign at the real estate data company. The fund intends to nominate multiple directors to CoStar's eight-person board and push management to concentrate on commercial real estate while divesting or shutting down recently ex…